KalVista Pharmaceuticals, Inc. (KALV)
KALV moved a median of 0.00% 30 minutes after news, and -0.10% by the close. How KALV actually reacts to news — the realized, point-in-time move the market made, measured across 438 labeled events over the last three years with zero look-ahead.
KALV’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 41% | 400 |
| 30-min | 0.00% | 50% | 400 |
| 60-min | -0.02% | 48% | 400 |
| to close | -0.10% | 46% | 400 |
| Middle 50% of KALV reactions | -1.26% to +0.71% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 438 |
Half of all KalVista Pharmaceuticals, Inc. news events land between -1.26% and +0.71% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How KALV reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 14 | +0.03% | 64% | -0.04% |
| Coverage initiations | 11 | -0.27% | 46% | -2.12% |
| Rating reiterations | 59 | -0.45% | 36% | -0.81% |
| Price-target raises | 10 | -0.88% | 40% | -3.11% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how KALV ranks against every other measured name →
That’s how KALV usually reacts — get an email when it moves on news →Email me when KALV moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KALV's baseline. Nothing else.
Recent KALV events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G KalVista Pharmaceuticals | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT KalVista Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Chiesi Group Completes Acquisition of KalVista Pharmaceuticals | Press release | Business Wire | — | — | |
| Form 8-K KalVista Pharmaceuticals For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM KalVista Pharmaceuticals | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS KalVista Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema | Press release | Business Wire | +0.02% | -0.07% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – | Press release | GlobeNewswire | +0.02% | -0.04% | |
| Form 10-Q KalVista Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -0.19% | |
| Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.04% | -0.07% | |
| Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.02% | +0.02% | |
| Form 10-KT/A KalVista Pharmaceuticals For: Dec 31 | SEC filing · Form 10-KT | SEC EDGAR | +0.04% | -0.04% | |
| Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio | Press release | Business Wire | +0.11% | -0.11% | |
| Form 8-K KalVista Pharmaceuticals For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | +0.11% | -0.11% | |
| KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | +0.00% | -0.11% | |
| KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference | Press release | Business Wire | +0.12% | -6.86% | |
| KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.25% | +1.35% | |
| KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference | Press release | Business Wire | -0.63% | -3.17% | |
| Form 10-KT KalVista Pharmaceuticals For: Dec 31 | SEC filing · Form 10-KT | SEC EDGAR | -1.53% | +11.67% | |
| Form 8-K KalVista Pharmaceuticals For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | -0.12% | -0.17% | |
| KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update | Press release | Business Wire | -0.12% | -0.17% | |
| KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 | Press release | Business Wire | -0.75% | -7.13% | |
| KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.54% | +4.13% | |
| KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) | Press release | Business Wire | +2.14% | +1.13% | |
| KalVista Pharmaceuticals to Present at Upcoming Investor Conferences | Press release | Business Wire | +0.70% | -0.19% | |
| KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline | Press release | Business Wire | +0.30% | +3.00% | |
| KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting | Press release | Business Wire | -0.70% | -3.69% | |
| KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +2.44% | +0.25% | |
| Form S-8 KalVista Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | +2.03% | +0.88% | |
| Form 8-K KalVista Pharmaceuticals For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -1.45% | -9.68% | |
| KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results | Press release | Business Wire | -1.45% | -9.68% | |
| KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema | Press release | Business Wire | +1.89% | +3.39% | |
| Form 10-Q KalVista Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.36% | +0.70% | |
| Form 8-K KalVista Pharmaceuticals For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | -5.36% | +0.70% | |
| KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results | Press release | Business Wire | -5.36% | +0.70% | |
| KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting | Press release | Business Wire | +0.32% | -0.73% | |
| KalVista Pharmaceuticals to Present at Upcoming Investor Conferences | Press release | Business Wire | -1.11% | +1.85% | |
| KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025 | Press release | Business Wire | +2.17% | -0.18% | |
| KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting | Press release | Business Wire | +0.82% | -0.27% | |
| Form 8-K KalVista Pharmaceuticals For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -2.33% | -8.82% | |
| KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer | Press release | Business Wire | -2.33% | -8.82% | |
| KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe | Press release | Business Wire | +0.09% | -0.09% | |
| KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.27% | +0.34% | |
| Form 8-K KalVista Pharmaceuticals For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | -2.49% | |
| KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors | Press release | Business Wire | -0.17% | -2.49% | |
| Form 8-K KalVista Pharmaceuticals For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.25% | |
| KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress | Press release | Business Wire | -0.17% | +2.31% | |
| KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes | Press release | Business Wire | -4.01% | -3.01% | |
| KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031 | Press release | Business Wire | -4.01% | -3.01% | |
| KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema | Press release | Business Wire | -1.14% | -6.33% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KALV section they belong to.
Where else KALV is measured.
KALV earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EyePoint, Inc. (EYPT) | 439 | -0.25% | 46% |
| Abeona Therapeutics Inc. (ABEO) | 438 | +0.09% | 51% |
| Zymeworks Inc. (ZYME) | 438 | 0.00% | 50% |
| Exact Sciences Corporation (EXAS) | 437 | +0.08% | 56% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is KalVista Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled KALV news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 438 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of KALV's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KALV's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.